Rapid olfactory tools for telemedicine-friendly COVID-19 screening and surveillance

用于远程医疗友好型 COVID-19 筛查和监测的快速嗅觉工具

• 批准号: 10263657
• 负责人: Richard C Gerkin
• 金额: $ 48.54万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-12-21 至 2022-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10263657
• 关键词: 2019-nCoV; Administrator; Anosmia; Appalachian Region; Arizona; COVID-19; COVID-19 pandemic; COVID-19 screening; COVID-19 surveillance; COVID-19 testing; Clinical; Collection; Common Cold; Communicable Diseases; Communities; Complement; Coughing; Country; Custom; Dangerousness; Data; Detection; Diagnosis; Diagnostic; Differential Diagnosis; Disadvantaged; Discrimination; Disease; Disease Outbreaks; Early identification; Economics; Employee; Encapsulated; Fever; Florida; Government; Health; Healthcare Systems; Heterogeneity; Hot Spot; Individual; Influenza; Infrastructure; Laboratories; Link; Logistics; Measures; Methods; Monitor; Municipalities; National Health and Nutrition Examination Survey; Native Americans; Odors; Olfactory dysfunction; Outcome; Participant; Patient Self-Report; Pennsylvania; Persons; PhenX Toolkit; Play; Population; Population Surveillance; Prevalence; Procedures; Public Health; Quarantine; Questionnaires; Rapid screening; Reporting; Safety; Sampling; Screening procedure; Self Administration; Sentinel; Specificity; Symptoms; System; Telemedicine; Telephone; Testing; Time; United States; United States National Institutes of Health; Universities; Upper Respiratory Infections; Viral; Virus; Workplace; authority; base; community setting; cost; cost effective; dalton; design; hyposmia; member; novel; screening; smell test; social health determinants; tool; university student

The COVID-19 pandemic is the most devastating infectious disease outbreak in a century, particularly in underserved and minoritized communities. In 2020 alone, it will cost a million lives. It continues to wreak economic havoc worldwide. Therefore, it is critical to develop new tools that can mitigate the spread of SARS- CoV-2, the virus that causes COVID-19. Rapid screening tools can identify potentially infected individuals who can then be isolated/quarantined from the uninfected and directed towards further testing and treatment. Unfortunately, definitive viral testing for SARS-CoV-2 has proven difficult to implement in many countries, including the US, due to technical, financial and governmental hurdles to universal access and timely processing. Symptom-based screening offers a valuable, albeit imperfect, complement to viral testing that can help identify many individuals with the disease for isolation as well as treatment. A major challenge with symptomatic testing is that COVID-19 is highly protean: the heterogeneity of symptoms means no single symptom or constellation of symptoms is definitive diagnostically. Still, there is growing evidence that sudden partial or complete olfactory loss – even more than other symptoms such as fever or dry cough – is the single best predictor of COVID-19. In this proposal, we will develop and implement objective, self-administered smell tests for the purpose of identifying individuals with COVID-19 prior to, or in the absence of, viral testing, as well as for use in population-level surveillance of COVID-19 spread. Several kinds of objective tests have been used in clinical or laboratory settings to assess an individual's olfactory ability, including those that test the ability to identify or discriminate odors as well as procedures to determine the lowest concentration an individual can reliably perceive (i.e., odor detection threshold). Each approach has technical and logistical advantages and disadvantages, and each captures different aspects of olfactory dysfunction. Regarding COVID-19, it is unknown what type of measure has the highest specificity or sensitivity. In Aim 1, we will use self-administered objective testing of odor identification and odor detection threshold in SARS-CoV-2-tested individuals to determine which olfactory measure is the best predictor of COVID-19. In Aim 2, we will use objective smell testing to assess whether population monitoring of olfactory loss in university, municipal or other community settings can serve as a sentinel of COVID-19 community spread. Together, our studies will provide a rapid, remote-friendly, cost-effective, scalable, non-intrusive method to screen for COVID-19 at the individual level and to assess prevalence in communities, especially those that have been traditionally underserved by the health care system and public health infrastructure.

COVID-19大流行是一个世纪以来最具破坏性的传染病爆发，尤其是在 服务不足和少数社区。仅在2020年，这将花费一百万的生命。它继续醒来 全球经济严重破坏。因此，开发可以减轻SARS-的新工具的新工具至关重要。 COV-2，导致COVID-19的病毒。快速筛选工具可以识别潜在感染的人 然后可以与未感染的人分离/隔离，并指向进一步的测试和治疗。 不幸的是，事实证明，SARS-COV-2的确定病毒测试在许多国家中很难实施， 包括美国在内，由于技术，财务和政府的障碍，可以及时获得通用的障碍 加工。基于症状的筛查提供了有价值的，尽管不完美，但对病毒测试的补充可以 帮助识别许多患有疾病的人进行隔离和治疗。一个主要的挑战 有症状的测试是Covid-19是高度蛋白质的：症状的异质性意味着没有单一 症状或症状星座是明确诊断的。尽管如此，越来越多的证据突然 部分或完全嗅觉损失（甚至比发烧或干coug）更多的是单一症状 - COVID-19的最佳预测指标。在此提案中，我们将开发和实施目标，自我管理的气味 测试目的是在或在没有病毒测试之前识别COVID-19的个体 至于在COVID-19的人口水平监视中使用。几种客观测试已经 在临床或实验室环境中用于评估个人的嗅觉能力，包括测试的能力 识别或区分气味的能力以及确定最低浓度的程序 个体可以可靠地感知（即气味检测阈值）。每种方法都有技术和后勤 优势和缺点，每个都捕获了嗅觉功能障碍的不同方面。关于 COVID-19，尚不清楚哪种类型的度量具有最高的特异性或灵敏度。在AIM 1中，我们将使用 SARS-COV-2测试中的气味识别和气味检测阈值的自我管理的客观测试 在AIM 2中，我们将使用个人来确定哪种嗅觉度量是Covid-19的最佳预测指标。 客观气味测试以评估大学，市政或 其他社区环境可以用作Covid-19社区传播的前哨。一起，我们的研究将 提供一种快速，遥不可及的，具有成本效益，可扩展性，无侵入性的方法，以筛选在19号 个人水平并评估社区的流行，尤其是传统上的人 由医疗保健系统和公共卫生基础设施服务不足。